-+ 0.00%
-+ 0.00%
-+ 0.00%
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
Share
Listen to the news

Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma ("DLBCL"), with Seoul St. Mary’s Hospital identified as the lead clinical site.

Under the engagement, Synex will provide clinical research services pursuant to a milestone-based program, with payments linked to key clinical development milestones, including patient enrollment, database lock and completion of the clinical study report.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending